Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Alzheimer’s Disease: 8th most common cause of death

15.03.2005


International experts gather in UCD this week (14-16 March 2005)* to discuss medical research into neurodegenerative diseases including the eighth most common cause of death in the developed world ¡V Alzheimer¡¦s Disease.

Alzheimer¡¦s Disease is a degenerative brain disorder that primarily affects older people. It may begin with simple forgetfulness but more advanced symptoms include confusion, language disturbances, personality and behaviour changes and impaired judgment. The disease duration can span from two to twenty years and the economic cost to families and society is enormous. US estimates put the cost of the disease there at $80 -100 billion per annum.

Dr Dominic Walsh from UCD¡¦s Conway Institute and a leading expert in Alzheimer¡¦s, has warned that, with its aging population, Ireland is sitting on a geriatric medical timebomb if the Government does not actively set the treatment of neurodegenerative diseases as a coherent research priority. ¡§The investment by Science Foundation Ireland (SFI) has been monumental in providing a base for world class scientific research in Ireland. However, we need to focus efforts across the Irish universities into areas where we can create a critical mass of research to make breakthroughs that will impact directly on Irish society.¡¨ He said.



Taking statistics from the US, the reality is that up to 50% of the population over 85 years of age suffer from Alzheimer¡¦s Diseases. Current estimates suggest that over 35,000 people in Ireland suffer with Alzheimer¡¦s disease and a further 30,000 have other lesser-known dementias. The single largest risk factor for developing Alzheimer¡¦s is age. Consequently, as life-expectancy increases so too will the incidence of dementia.

Dr Walsh is among 250 delegates from across the world working on different aspects of neurodegenerative diseases. Dr Walsh¡¦s work concentrates on the processes leading to plaque formation and the toxic events that result from it. He led the group that first identified toxic non-plaque forms of the amyloid protein and more recently has shown that these species can disrupt normal nerve cell activity and the ability to form and retrieve memory.

Alzheimer¡¦s is characterised by two pathological hallmarks; amyloid plaques and neurofibrillary tangles. Amyloid plaques are composed of a protein, the amyloid beta-protein (A£]) that is normally produced in every tissue of the body. A£] is a fragment of a protein that is snipped from another protein called the amyloid precursor protein (APP). In a healthy brain, A£] would be broken down and eliminated but in Alzheimer’s disease, it accumulates to form insoluble amyloid plaques. Neurofibrillary tangles, which are believed to develop as a consequence of the build up of toxic A£] ƒzconsist of insoluble twisted fibres that are found inside brain cells. They primarily consist of a protein called tau, which is involved in neuronal transport delivering nutrients and other important substances from one part of the nerve cell to another. In Alzheimer’s disease, however, the tau protein is malformed and normal transport is blocked

Scientists believe that if they can reduce the accumulation of toxic A£], they will be able to ultimately cure the disease.

Among the internationally renowned experts speaking at the conference are:

Professor Dennis Selkoe, Harvard Medical School, is widely regarded as the leading expert in the field of Alzheimer research and has made a number of major breakthroughs in the area.

Professor John Hardy, director of the Laboratory of Neurogenetics, National Institutes of Health who discovered the first mutation (in APP) associated with inherited forms of Alzheimer¡¦s disease.

Dr Martin Citron, head of neurodegenerative research, Amgen, who was nominated by Time magazine in the nineties as one of the ¡¥most intriguing people of decade¡¦. Dr Citron progressed research by identifying one of the enzymes required for A£] ƒngeneration.

Medical research generally takes years to progress from a laboratory setting to clinical trials and eventually into general use for disease sufferers. Currently Elan and Wyeth are conducting Phase I trials for a passive immunisation treatment that involves injecting anti-A£] ƒnantibodies into the bloodstream of a small number of selected patients. Potentially successful therapeutics if approved, will progress to Phase II with a wider group of carefully monitored patients and then a larger Phase III trial involving longer-term treatment and a large number of volunteers. Before a drug can hit the market researchers must satisfy the requirements of drug regulatory authorities (the FDA in the US and the IMB in Ireland) with respect to the safety and effectiveness of the treatment.

*The Molecular Mechanisms of Neurodegeneration conference is a joint Biochemical Society/Neuroscience Ireland focused meeting under the chairmanship of Dr Dominic Walsh.

The full programme is accessible on: http://www.ucd.ie/conway/event_9.html

Elaine Quinn | alfa
Further information:
http://www.ucd.ie/conway/event_9.html

More articles from Health and Medicine:

nachricht Using fragment-based approaches to discover new antibiotics
21.06.2018 | SLAS (Society for Laboratory Automation and Screening)

nachricht Scientists learn more about how gene linked to autism affects brain
19.06.2018 | Cincinnati Children's Hospital Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Temperature-controlled fiber-optic light source with liquid core

In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.

Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...

Im Focus: Overdosing on Calcium

Nano crystals impact stem cell fate during bone formation

Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...

Im Focus: AchemAsia 2019 will take place in Shanghai

Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.

Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...

Im Focus: First real-time test of Li-Fi utilization for the industrial Internet of Things

The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.

Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.

Im Focus: Sharp images with flexible fibers

An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.

Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Munich conference on asteroid detection, tracking and defense

13.06.2018 | Event News

2nd International Baltic Earth Conference in Denmark: “The Baltic Sea region in Transition”

08.06.2018 | Event News

ISEKI_Food 2018: Conference with Holistic View of Food Production

05.06.2018 | Event News

 
Latest News

Graphene assembled film shows higher thermal conductivity than graphite film

22.06.2018 | Materials Sciences

Fast rising bedrock below West Antarctica reveals an extremely fluid Earth mantle

22.06.2018 | Earth Sciences

Zebrafish's near 360 degree UV-vision knocks stripes off Google Street View

22.06.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>